Schirmer previously led McCann Global Health as president for nearly five years.
AI's marketing problem: Inflated claims, outsized expectations may actually be slowing AI's move into clinical practice
The potential is real, but companies and technology gurus often speak of machine learning as a catch-all solution. The hype may be slowing AI's incremental growth in healthcare, experts say.
The general sense: Nobody should get comfortable with the status quo
Anti-opioid-abuse funding in federal budget bill, healthcare market stabilization out; Redfield tapped to lead CDC; Healthcare companies look to pharma for leadership.
Philip Thomas takes over from Terry Savage.
The council, made up of seasoned pharma execs, will function as consultants to rbb's health clients and health team.
J&J CFO plans September retirement; GSK pharma chief to turn business towards oncology, immunology; MM&M unveils 2018 list of healthcare transformers, innovation catalysts.
Interpublic Group chairman and chief executive told Advertising Week Europe how he managed to turn an "all white, all male" company into one with 54% female leadership.
Roche's immunotherapy Tecentriq, when combined with a Abraxane-based chemo, decreased the risk of disease worsening or death compared to chemo alone in first-line patients with advanced squamous non-small cell lung cancer; President Trump spoke about using federal prosecutors to sue opioid makers; Trump also vowed to bring down the cost of prescription drugs.
Congress has spent less than a quarter of the $500 million to fight the opioid epidemic; The #MeToo movement is gaining steam in the medical industry; Dr. Robert R. Redfield, a leading AIDS researcher, is the top candidate to lead the Centers for Disease Control and Prevention.
The pace may even pick up again this year.
The research will also cover topics including disease awareness ads.
Pfizer persuades Read to stay another year; House GOP to take another crack at "right to try"; Lundbeck plans to acquire Prexton Therapeutics.
How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.
FDA moves to limit nicotine in cigarettes; Alexion reports positive test for rare blood disorder treatment; Oregon governor signs drug pricing transparency bill.
MM&M spoke with Gazzaley about what's next for Akili, how he defines "digital medicine," and where the field is currently positioned on the hype cycle.
Why the U.S. spends more on healthcare with worse results; Alnylam goes it alone on rare disease therapy; MorphoSys hopes for accelerated approval on MOR208.
As drugmakers continue to experiment with novel pricing models for expensive new specialty drugs, MM&M asked a trio of industry insiders whether outcomes-based pricing should become standard.